mrna News
-
Cellumed and ARTES Sign Development and License Agreement
Today, Cellumed Co. Ltd., listed stock market company and Germany based ARTES Biotechnology GmbH announce the execution of a Development and License Agreement aiming at the generation of microbial production cell lines, processes and documentation for the cGMP manufacturing of two enzymes required in the manufacturing process of mRNA vaccines. Under this agreement, ARTES shall be responsible for ...
-
Foundational RNA and cLNP expert Antonin (Tony) de Fougerolles joins etherna as independent board member
Follows recent financing round led by Novalis LifeSciences LLC, with investors Dr. Marijn Dekkers and Moderna’s co-founder Dr. Kenneth Chien joining the board of directors Strategic focus includes customized lipid nanoparticles (cLNPs) mRNA chemistries and process capabilities as enabling technologies driving company excellence etherna (“the Company”), a leading ...
By eTheRNA
-
Almirall and etherna enter into a multi-target alliance to develop mRNA-based therapies in medical dermatology
The multi-target research and development partnership will focus on severe skin diseases The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space In addition to upfront and technology access payments, etherna is eligible to receive €300 million in development and commercial ...
By eTheRNA
-
Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced new data from preclinical studies of its GalXC-Plus™ RNAi technology demonstrating its potential to deliver deep and sustained messenger RNA (mRNA) knockdown against prespecified gene ...
-
BOC Sciences Celebrates Nobel Prize Awarded to Scientists Behind COVID-19 Vaccines
BOC Sciences expressed its congratulations to Katalin Karikó and Drew Weissman for being recipients of the 2023 Nobel Prize in Physiology or Medicine. The Royal Swedish Academy of Sciences recognized Dr. Karikó and Dr. Weissman's remarkable contributions to science, specifically acknowledging their game-changing discoveries in nucleoside base modifications. BOC Sciences, which ...
By BOC Sciences
-
CellFE platform enables microfluidic Transfection of mRNA into T cells and HSPCs
CellFE Biotech, a microfluidics-based biotech startup based out of Alameda, CA, has recently had an article published in Scientific Reports. The article, cited below, focuses on the use of a novel microfluidics platform to successfully achieve the transfection of mRNA into T-cells, particularly through volume exchange for convective transfection (VECT). The delivery of mRNA offers a distinct ...
By CellFE
-
mRNA/LNP technology platform company etherna names Bernard Sagaert as Chief Executive Officer and Marijn Dekkers as Chairman of the Board
Sagaert’s CEO appointment follows his successful interim period implementing etherna’s new partnership-driven business strategy. Sagaert joined etherna in 2017 and brings extensive operational and strategic experience in the life sciences industry. Dekkers, who is the founder of investment and advisory firm Novalis Capital Partners LLC and former CEO of Bayer AG and Thermo ...
By eTheRNA
-
CD Bioparticles Launches mRNA Transfection Reagents for Research Applications
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, recently introduced a line of highly efficient mRNA Transfection Reagents with low toxicity for research applications, including the mRNA Transfection Reagent, Stem mRNA Transfection Reagent, and mRNA/gRNA Transfection Reagent. mRNA transfection is the process of introducing and expressing mRNA ...
-
Alfa Chemistry Excels in mRNA Vaccine Development, Production, Optimization, and Quality Control
In the face of global health crises such as the COVID-19 pandemic, the development and production of vaccines have become paramount to safeguarding public health and restoring normalcy. Among the various vaccine technologies, mRNA vaccines have emerged as a groundbreaking solution, offering promising results in the fight against infectious diseases. Alfa Chemistry, a renowned scientific research ...
-
CD Genomics RNA-Solutions Platform Now Provides Whole Transcriptome Sequencing Service
RNA-Solutions is a platform for revolutionary research in RNA, targeting coding and non-coding RNAs with different physiological functions. Scientists at CD Genomics are ready to help detect various types of RNAs via meticulous and integrative approaches. Powered by the Illumina, Pacbio SMRT, and Nanopore sequencing platforms, CD Genomics offers services performed by de novo and reference-based ...
By CD Genomics
-
Ribo-Seq Service Now Available on CD Genomics’s RNA Solutions Platforms
RNA Solutions is the platform that offers services on the revolutionizing study of RNA, targeting both coding and non-coding RNAs of different physiological functions. The scientists at CD Genomics are ready to help detect various types of RNA via meticulous and integrative approaches. To further enrich its service types, the company recently announced to add Ribo-Seq to its offerings. ...
By CD Genomics
-
Visit of His Majesty the King of the Belgians Philippe and Her Majesty the Queen of the Belgians Mathilde to Afrigen Biologics
HM King Philippe and HM Queen Mathilde, currently on a state visit to South Africa until March 27, visited the Afrigen Biologics facility in Cape Town to learn more about how two Belgian companies, Univercells and etherna, are supporting the development of the first African- developed mRNA COVID-19 vaccine. The King and The Queen are accompanied by five ministers of federal and regional ...
By eTheRNA
-
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS (“bYoRNA”) today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA (“mRNA”). Dyadic is a global biotechnology company focused on building innovative ...
-
Feasibility study initiated to develop a novel drug carrier to deliver oligonucleotides, ASO and siRNA
CIS Pharma has initiated a feasibility study to develop a novel carrier to conjugate ASO and siRNA for targeted delivery, in collaboration with the University of Applied Sciences in Basel. To widen the therapeutic use of oligonucleotides, CIS Pharma is developing technology for bio-conjugation of RNAi to targeting moieties, similar to the targeting technology developed for cancer therapies. The ...
-
CD Genomics RNA-Solutions Platform Unveils m7G MeRIP Sequencing for Scientific Research
RNA-Solutions is a platform for revolutionary research in RNA, targeting coding and non-coding RNAs with different physiological functions. Scientists at CD Genomics are ready to help detect various types of RNAs via meticulous and integrative approaches. Recently, the company has launched m7G MeRIP sequencing to detect and analyze m7G RNA modification in a single sample, providing a powerful ...
By CD Genomics
-
SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo
WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today shared enhanced antigen presenting cell (eAPC) preclinical data demonstrating that delivery of multiple mRNAs encoding for disease-specic antigens together with immune stimulators (CD86 costimulatory factor and membrane bound IL-2 and ...
-
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy Pfizer gains option to license Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development Pfizer Inc. (NYSE: PFE) and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems ...
-
BOC Sciences 2022 Free Webinar: Viral RNA Modifications and Implications for Novel Therapeutics
BOC Sciences grandly announced the schedule of a free webinar on September 19th, 2022, at 11:00 EDT, which is a laudable event centering on the hot spot of RNA research during the pandemic. BOC Sciences is an expert in RNA technologies. It is now renowned as the largest manufacturer of pseudoUridine and its derivatives, the critical materials for RNA modification. BOC Sciences' annual ...
By BOC Sciences
-
m5C Profiling Services Now Available by CD Genomics`s RNA Solutions Platform
RNA Solutions is the platform that offers services on the revolutionizing study of RNA, targeting both coding and non-coding RNAs of different physiological functions. The CD Genomics scientists are ready to help detect various types of RNA via meticulous and integrative approaches. These days, the product manager of CD Genomics announced the m5C profiling services to help researchers deeply ...
By CD Genomics
-
Metadata Editing Using Manifest Files Just Got Easier
Seven Bridges Platform provides the capability to modify metadata for multiple files in a project by using the Export metadata manifest and Edit metadata with manifest options in the File Browser. This release brings some major improvements to this feature: Support for different manifest file formats. Besides CSV, we have added support for the TSV file format. Use either file name or ID to ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you